Connor Clark & Lunn Investment Management Ltd. Purchases 99,324 Shares of Pediatrix Medical Group, Inc. (NYSE:MD)

Connor Clark & Lunn Investment Management Ltd. raised its position in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 60.5% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 263,410 shares of the company's stock after acquiring an additional 99,324 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.31% of Pediatrix Medical Group worth $3,053,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. nVerses Capital LLC bought a new position in shares of Pediatrix Medical Group in the 2nd quarter valued at about $31,000. Innealta Capital LLC bought a new position in Pediatrix Medical Group in the second quarter valued at approximately $33,000. Quest Partners LLC increased its position in shares of Pediatrix Medical Group by 25.6% during the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company's stock worth $35,000 after purchasing an additional 622 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Pediatrix Medical Group by 47.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company's stock worth $36,000 after purchasing an additional 1,524 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Pediatrix Medical Group during the 2nd quarter worth approximately $72,000. Institutional investors and hedge funds own 97.71% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on MD shares. Truist Financial upped their target price on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a "hold" rating in a report on Monday, November 4th. Deutsche Bank Aktiengesellschaft upped their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a "hold" rating in a research note on Monday, November 4th. StockNews.com downgraded Pediatrix Medical Group from a "buy" rating to a "hold" rating in a research note on Thursday. UBS Group increased their price target on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Finally, Mizuho lifted their price objective on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 19th. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $16.10.

Pediatrix Medical Group Stock Performance

NYSE MD traded down $0.20 on Monday, reaching $14.76. The stock had a trading volume of 954,146 shares, compared to its average volume of 866,112. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42. The company has a market cap of $1.27 billion, a P/E ratio of -4.82, a price-to-earnings-growth ratio of 2.12 and a beta of 1.55. The firm has a fifty day moving average of $13.01 and a two-hundred day moving average of $10.10. Pediatrix Medical Group, Inc. has a 1-year low of $6.62 and a 1-year high of $16.41.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its quarterly earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.37 by $0.07. The business had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. Pediatrix Medical Group's revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the firm earned $0.29 earnings per share. On average, equities research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.26 EPS for the current year.

Insider Activity

In other news, Director Mark S. Ordan sold 27,600 shares of the company's stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the completion of the sale, the director now owns 138,683 shares of the company's stock, valued at approximately $2,128,784.05. This represents a 16.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the company's stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the sale, the executive vice president now owns 135,810 shares of the company's stock, valued at approximately $2,172,960. This represents a 5.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 53,808 shares of company stock worth $751,277. Corporate insiders own 2.00% of the company's stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.